Revisit recent top news in ophthalmology
A look at Demodex blepharitis and an FDA approval led ophthalmology news in the first week of April.
Read the recent best performing articles below.
Demodex: Easy to find, not so easy to kill
The Demodex mite, of which there are at least 65 species, is the most common microscopic ectoparasite found on human skin. Demodex folliculorum is responsible for Demodex blepharitis, which accounts for at least 45% of blepharitis cases. Read more.
FDA approves Bausch + Lomb’s ClearVisc OVD
Bausch + Lomb’s ClearVisc dispersive ophthalmic viscosurgical device has received FDA approval for use in ophthalmic surgery. Read more.
Eylea reduces chance of vision-threatening complications in Protocol W
Two-year results of an ongoing study show that intravitreal aflibercept injections in eyes with baseline moderate to severe nonproliferative diabetic retinopathy significantly decrease the chance to develop vision-threatening complications. Read more.
Horizon receives authorization to increase Tepezza production
Horizon Therapeutics has received a prior approval supplement for its previously approved biologics license application so that it can manufacture more Tepezza for the treatment of thyroid eye disease. Read more.
Managing myopia in pediatric patients is not a one-answer solution
Patients with high myopia can be at risk for ocular pathology, so managing, slowing and treating myopia in pediatric patients with drugs, multifocal contact lenses and refractive surgery are necessary. Read more.